Jankovic J
Neurology. 1983 Apr;33(4):505-7. doi: 10.1212/wnl.33.4.505.
We evaluated pergolide in 22 patients with Parkinson's disease and 3 with progressive supranuclear palsy (PSP). After achieving an optimal dose of pergolide and Sinemet, a matching placebo was substituted in double-blind manner. The mean dose of levodopa (in Sinemet) was reduced by 68%; in eight patients, pergolide completely replaced levodopa. In parkinsonian patients, the mean Hoehn-Yahr stage decreased from 3.2 to 1.6, and the mean total disability score decreased from 48.3 to 17.8. In 10 patients with on-off phenomenon, the time on increased 174% with pergolide. There was little effect in PSP. Postural light-headedness and reversible mental changes were seen.
我们对22例帕金森病患者和3例进行性核上性麻痹（PSP）患者使用培高利特进行了评估。在达到培高利特和息宁的最佳剂量后，以双盲方式替换为匹配的安慰剂。左旋多巴（在息宁中）的平均剂量降低了68%；在8例患者中，培高利特完全替代了左旋多巴。在帕金森病患者中，平均Hoehn-Yahr分期从3.2降至1.6，平均总残疾评分从48.3降至17.8。在10例有开关现象的患者中，使用培高利特后开期时间增加了174%。在PSP患者中效果甚微。出现了体位性头晕和可逆性精神改变。
